Glasgow spin-out raises £9.7 million for early-stage cancer test

A Glasgow-based company developing a blood test that can detect cancer at an early stage has raised £9.7m through a Series A investment and grant funding.

The £7.5m funding round was led by existing investors Eos Advisory, Mercia Asset Management, Scottish Enterprise, University of Strathclyde, SIS Ventures and Norcliffe Capital, joined by US-based life science investor Mark Bamforth of Thairm Bio.

Dxcover also secured a £2.2m grant from the European Innovation Council.

The money will support the ongoing development of the Dxcover Liquid Biopsy Platform for the detection of early-stage cancers, including brain and colorectal cancers.

Read more HERE.